Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Experimed is Scopus-indexed (Q4, CiteScore 0.4), WoS ESCI, DOAJ. Published by Istanbul University Press.
Checked against the index lists dated .
ISSN 2667-5846Verify ISSN ↗
Publisher: Istanbul University Press
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medicine (miscellaneous) | 406 / 466 | 12th | Q4 |
| Oncology | 382 / 428 | 10th | Q4 |
| Genetics (clinical) | 96 / 100 | 4th | Q4 |
| Biochemistry (medical) | 75 / 78 | 4th | Q4 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2019–2025, best quartile Q4, CiteScore 0.4.
Experimed is Q4 in Medicine (miscellaneous) (rank 406 of 466), Q4 in Oncology (rank 382 of 428) and Q4 in Genetics (clinical) (rank 96 of 100), by CiteScore 2025. It is ranked in 4 subject areas in all.
Experimed is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 0.4, which places it in quartile Q4 at the 12th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.135, quartile Q4, with an H-index of 5.
Experimed is published by Istanbul University Press. Its ISSN is 2667-5846.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Experimed has an h-index of 6 and a 2-year mean of 0.2 citations per paper (OpenAlex). Its Scopus CiteScore is 0.4, quartile Q4. On 2-year citations it ranks #380 of 451 Scopus journals in Medicine (miscellaneous).
Experimed published 34 papers in 2025; its busiest recent year was 2022 with 38. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 34 research articles (2023–2026), authors are most often from Türkiye (86.8%), Iran (4.4%) and Cyprus (2.9%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.